May 16, 2018 / 3:56 PM / 2 months ago

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

May 16 (Reuters) - Audentes Therapeutics Inc:

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

* PATIENT 1 HAS ACHIEVED VENTILATOR INDEPENDENCE AND ORAL FEEDING

* SIGNIFICANT IMPROVEMENTS IN NEUROMUSCULAR AND RESPIRATORY FUNCTION AT 24-WEEK TIMEPOINT

* HAVE BEEN TOTAL OF 24 ADVERSE EVENTS REPORTED IN ASPIRO, SIX OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS

* THERE HAVE BEEN AN ADDITIONAL 11 NON-SERIOUS AES IN ASPIRO, ALL DETERMINED TO BE NOT TREATMENT-RELATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below